273 related articles for article (PubMed ID: 18445186)
1. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy?
Allam JP; Stojanovski G; Friedrichs N; Peng W; Bieber T; Wenzel J; Novak N
Allergy; 2008 Jun; 63(6):720-7. PubMed ID: 18445186
[TBL] [Abstract][Full Text] [Related]
2. Mucosal dendritic cells in allergy and immunotherapy.
Novak N; Allam JP
Allergy; 2011 Jul; 66 Suppl 95():22-4. PubMed ID: 21668846
[TBL] [Abstract][Full Text] [Related]
3. Immune mechanisms of allergen-specific sublingual immunotherapy.
Moingeon P; Batard T; Fadel R; Frati F; Sieber J; Van Overtvelt L
Allergy; 2006 Feb; 61(2):151-65. PubMed ID: 16409190
[TBL] [Abstract][Full Text] [Related]
4. Immunological mechanisms of sublingual allergen-specific immunotherapy.
Novak N; Bieber T; Allam JP
Allergy; 2011 Jun; 66(6):733-9. PubMed ID: 21251016
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells.
Allam JP; Peng WM; Appel T; Wenghoefer M; Niederhagen B; Bieber T; Bergé S; Novak N
J Allergy Clin Immunol; 2008 Feb; 121(2):368-374.e1. PubMed ID: 18036651
[TBL] [Abstract][Full Text] [Related]
6. Characterization of oral immune cells in birch pollen-allergic patients: impact of the oral allergy syndrome and sublingual allergen immunotherapy on antigen-presenting cells.
Mascarell L; Rak S; Worm M; Melac M; Soulie S; Lescaille G; Lemoine F; Jospin F; Paul S; Caplier L; Hasséus B; Björhn C; Zeldin RK; Baron-Bodo V; Moingeon P
Allergy; 2015 Apr; 70(4):408-19. PubMed ID: 25631199
[TBL] [Abstract][Full Text] [Related]
7. Oral reactions to sublingual immunotherapy: a bioptic study.
Marcucci F; Sensi L; Incorvaia C; Di Cara G; Moingeon P; Frati F
Allergy; 2007 Dec; 62(12):1475-7. PubMed ID: 17983387
[No Abstract] [Full Text] [Related]
8. Local immunological mechanisms of sublingual immunotherapy.
Allam JP; Novak N
Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):571-8. PubMed ID: 22001742
[TBL] [Abstract][Full Text] [Related]
9. Different immunotherapy applications--different mechanisms? SLIT versus SCIT--differences in the mode of action.
Allam JP; Bieber T; Novak N
Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():237-40; discussion 240-5. PubMed ID: 20799467
[No Abstract] [Full Text] [Related]
10. Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction.
Saint-Lu N; Tourdot S; Razafindratsita A; Mascarell L; Berjont N; Chabre H; Louise A; Van Overtvelt L; Moingeon P
Allergy; 2009 Jul; 64(7):1003-13. PubMed ID: 19220212
[TBL] [Abstract][Full Text] [Related]
11. What do we need to learn to optimize the SLIT alternative?
Serra HM; Alignani DO; Passalacqua G; Canonica GW; Correa SG
Eur Ann Allergy Clin Immunol; 2006 May; 38(5):158-65. PubMed ID: 17058848
[TBL] [Abstract][Full Text] [Related]
12. Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta1 and IL-10-producing properties.
Allam JP; Würtzen PA; Reinartz M; Winter J; Vrtala S; Chen KW; Valenta R; Wenghoefer M; Appel T; Gros E; Niederhagen B; Bieber T; Lund K; Novak N
J Allergy Clin Immunol; 2010 Sep; 126(3):638-45.e1. PubMed ID: 20584546
[TBL] [Abstract][Full Text] [Related]
13. Sublingual vaccines based on wild-type recombinant allergens.
Van Overtvelt L; Razafindratsita A; St-Lu N; Didierlaurent A; Batard T; Lombardi V; Martin E; Moingeon P
Eur Ann Allergy Clin Immunol; 2006 Sep; 38(7):247-9. PubMed ID: 17124785
[TBL] [Abstract][Full Text] [Related]
14. Sublingual immunotherapy: from safety to mechanism of action.
Marcucci F; Sensi L; Allocca G; Chiarello F; Palleri P; Ugolini E; Di Rienzo A; Castellani S; Incorvaia C; Di Cara G; Puccinelli P; Frati F
Eur Ann Allergy Clin Immunol; 2007 Mar; 39(3):101-3. PubMed ID: 17465282
[TBL] [Abstract][Full Text] [Related]
15. Immunological mechanisms of sublingual immunotherapy.
Akdis CA; Barlan IB; Bahceciler N; Akdis M
Allergy; 2006; 61 Suppl 81():11-4. PubMed ID: 16792600
[TBL] [Abstract][Full Text] [Related]
16. An immunological overview of allergen specific immunotherapy -- subcutaneous and sublingual routes.
Ozdemir C
Ther Adv Respir Dis; 2009 Oct; 3(5):253-62. PubMed ID: 19880430
[TBL] [Abstract][Full Text] [Related]
17. New routes of allergen immunotherapy.
Aricigil M; Muluk NB; Sakarya EU; Sakalar EG; Senturk M; Reisacher WR; Cingi C
Am J Rhinol Allergy; 2016 Nov; 30(6):193-197. PubMed ID: 28124639
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells as potential targets for mucosal immunotherapy.
Allam JP; Bieber T; Novak N
Curr Opin Allergy Clin Immunol; 2009 Dec; 9(6):554-7. PubMed ID: 19745726
[TBL] [Abstract][Full Text] [Related]
19. Sublingual and oral immunotherapy.
Canonica GW; Compalati E; Fumagalli F; Passalacqua G
Immunol Allergy Clin North Am; 2004 Nov; 24(4):685-704, vii. PubMed ID: 15474866
[TBL] [Abstract][Full Text] [Related]
20. The immunoglobulin E-Toll-like receptor network.
Novak N; Bieber T; Peng WM
Int Arch Allergy Immunol; 2010; 151(1):1-7. PubMed ID: 19672091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
